A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).

Trial Details

NCT ID
NCT06528301
Phase
PHASE1
Sponsor
Umoja Biopharma
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • UB-VV111
  • rapamycin
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Chicago, Illinois, United States|41.85003,-87.65005
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Omaha, Nebraska, United States|41.25626,-95.94043
  • Cincinnati, Ohio, United States|39.12711,-84.51439

Key Eligibility Criteria

  • 18 years or older
  • Provides voluntary written informed consent
  • Relapsed or refractory large B-cell lymphoma (LBCL) or chronic lymphocytic leukemia (CLL)
  • Measurable disease according to Lugano 2014 criteria (LBCL) or iwCLL 2018 (CLL).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →